Critical appraisal of elvitegravir in the treatment of HIV-1/AIDS

Krishan K PandeyInstitute for Molecular Virology, Saint Louis University Health Sciences Center, St Louis, MO, USAAbstract: Human immunodeficiency virus type 1 (HIV-1) integrase inhibitors belong to a novel class of antiretroviral drugs with high potency and better tolerability. Elvitegravir (EVG)...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Pandey KK
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/c93ccd2a03dd4d348281ebbadd87a718
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c93ccd2a03dd4d348281ebbadd87a718
record_format	dspace
spelling	oai:doaj.org-article:c93ccd2a03dd4d348281ebbadd87a7182021-12-02T02:35:14ZCritical appraisal of elvitegravir in the treatment of HIV-1/AIDS1179-1373https://doaj.org/article/c93ccd2a03dd4d348281ebbadd87a7182014-05-01T00:00:00Zhttp://www.dovepress.com/critical-appraisal-of-elvitegravir-in-the-treatment-of-hiv-1aids-a16863https://doaj.org/toc/1179-1373 Krishan K PandeyInstitute for Molecular Virology, Saint Louis University Health Sciences Center, St Louis, MO, USAAbstract: Human immunodeficiency virus type 1 (HIV-1) integrase inhibitors belong to a novel class of antiretroviral drugs with high potency and better tolerability. Elvitegravir (EVG) is the second integrase inhibitor approved by the US Food and Drug Administration when administered in combination with a novel pharmacoenhancer, cobicistat (COBI), and two nucleoside/nucleotide reverse transcriptase inhibitors, emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF). This combination of drugs (EVG/COBI/FTC/TDF) developed and marketed by Gilead Sciences Inc. (Foster City, CA, USA) as STRIBILD®, is the first integrase inhibitor-based single-tablet regimen administered once-daily. In the USA, it has been approved for use in antiretroviral treatment-naïve HIV-1 patients with estimated creatinine clearance of >70 mL/min. The Department of Health and Human Services has approved EVG/COBI/FTC/TDF as one of preferred first-line regimens for HIV-1 treatment. In Europe, the European Medicines Agency has approved STRIBILD in treatment-naïve patients as well as in patients having no resistant mutation to any of the antiviral agents contained in STRIBILD. Its availability as a fixed-dose combination and once-daily dosage makes the adherence highly likely. However, it also discounts the possibility of dosage adjustment if needed.Keywords: STRIBILD, INSTI, integrase, EVG/COBI/FTC/TDFPandey KKDove Medical PressarticleImmunologic diseases. AllergyRC581-607ENHIV/AIDS: Research and Palliative Care, Vol 2014, Iss default, Pp 81-90 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607
spellingShingle	Immunologic diseases. Allergy RC581-607 Pandey KK Critical appraisal of elvitegravir in the treatment of HIV-1/AIDS
description	Krishan K PandeyInstitute for Molecular Virology, Saint Louis University Health Sciences Center, St Louis, MO, USAAbstract: Human immunodeficiency virus type 1 (HIV-1) integrase inhibitors belong to a novel class of antiretroviral drugs with high potency and better tolerability. Elvitegravir (EVG) is the second integrase inhibitor approved by the US Food and Drug Administration when administered in combination with a novel pharmacoenhancer, cobicistat (COBI), and two nucleoside/nucleotide reverse transcriptase inhibitors, emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF). This combination of drugs (EVG/COBI/FTC/TDF) developed and marketed by Gilead Sciences Inc. (Foster City, CA, USA) as STRIBILD®, is the first integrase inhibitor-based single-tablet regimen administered once-daily. In the USA, it has been approved for use in antiretroviral treatment-naïve HIV-1 patients with estimated creatinine clearance of >70 mL/min. The Department of Health and Human Services has approved EVG/COBI/FTC/TDF as one of preferred first-line regimens for HIV-1 treatment. In Europe, the European Medicines Agency has approved STRIBILD in treatment-naïve patients as well as in patients having no resistant mutation to any of the antiviral agents contained in STRIBILD. Its availability as a fixed-dose combination and once-daily dosage makes the adherence highly likely. However, it also discounts the possibility of dosage adjustment if needed.Keywords: STRIBILD, INSTI, integrase, EVG/COBI/FTC/TDF
format	article
author	Pandey KK
author_facet	Pandey KK
author_sort	Pandey KK
title	Critical appraisal of elvitegravir in the treatment of HIV-1/AIDS
title_short	Critical appraisal of elvitegravir in the treatment of HIV-1/AIDS
title_full	Critical appraisal of elvitegravir in the treatment of HIV-1/AIDS
title_fullStr	Critical appraisal of elvitegravir in the treatment of HIV-1/AIDS
title_full_unstemmed	Critical appraisal of elvitegravir in the treatment of HIV-1/AIDS
title_sort	critical appraisal of elvitegravir in the treatment of hiv-1/aids
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/c93ccd2a03dd4d348281ebbadd87a718
work_keys_str_mv	AT pandeykk criticalappraisalofelvitegravirinthetreatmentofhiv1aids
_version_	1718402374752534528

Critical appraisal of elvitegravir in the treatment of HIV-1/AIDS

Ejemplares similares